Drugs / Levilimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03103438 | Nov 2016 → May 2017 | — | Biocad | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03455842 | Feb → Dec 2018 | rheumatoid arthritis | Biocad | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05800327 | Dec 2022 → Sep 2024 overdue | rheumatoid arthritis | Biocad | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04397562 | Apr → Jul 2020 | COVID-19 | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT04227366 | Nov 2019 → Mar 2021 | rheumatoid arthritis | Biocad | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05800327 ↗ |
| Known as | BCD-089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04227366 ↗ |
| Known as | LVL | “receptor inhibitor levilimab (LVL) in subjects with severe COVID-19.” PMID 34586459 ↗ Sep 2021 |
| Action | Inhibit | “Subcutaneous injections of anti-IL6R every week” NCT03455842 ↗ |
| Modality | Monoclonal antibody | “a novel fully human monoclonal antibody against the interleukin-6 receptor” NCT03103438 ↗ |
| Route | Subcutaneous | “single subcutaneous injection of BCD-089” NCT03103438 ↗ |
| Target | IL6R | “monoclonal antibody to IL6R (BCD-089)” NCT03455842 ↗ |